medigraphic.com

2008, Number 1

<< Back Next >>

Cir Cir 2008; 76 (1)

Molecular classification of breast cancer

Zepeda-Castilla EJ, Recinos-Money E, Cuéllar-Hubbe M, Robles-Vidal CD, Maafs-Molina E

Language: Spanish
References: 42
Page: 87-93
PDF size: 130.00 Kb.


ABSTRACT

Breast cancer is classified based on clinical stage, cellular morphology and immunohistochemical analysis. More precise prognostic factors are necessary to aid with therapeutic decisions. Breast cancer subtypes that differ in their genetic expression and prognosis have been determined using cDNA microarrays. These findings confirm the differences between the phenotypes and provide new knowledge about the biology of breast cancer. Based on the presence or absence of expression of the estrogen receptor (ER), breast cancer is divided in two groups: ER+ and ER- The genetic expression profile has identified two subtypes of the ER+ tumors: luminal A and luminal B. ER- tumors also include two subtypes, the HER2+ and the basal type. These subtypes differ in their biology and both demonstrate short disease-free periods after treatment and poorer outcome. This classification has shown the relation between cDNA microarrays and clinical outcome of these tumors. This classification is proposed as a method of identifying those patients who will demonstrate better results with the different adjuvant modalities.


REFERENCES

  1. 1. Gradishar WJ. The future of breast cancer: the role of prognostic factors. Breast Cancer Res Treat 2005;89:S17-S26.

  2. 2. Boyle P. Breast cancer control: signs of progress, but more work required. Breast 2005;14:429–438.

  3. 3. Secretaría de Salud/Dir. Gral. de Epidemiología/Registro Histopatológico de Neoplasias Malignas/2002. http://www.dgepi.salud.gob.mx

  4. 4. Goldhirsch A, Glick JH, Gelber RD, Senn H. Meeting highlights: international consensus panel on the treatment of primary breast cancer. J Natl Cancer Inst 1998;90:1601-1608.

  5. 5. Goldhirsch A, Glick JH, Gelber RD, Coates AS, Thürlimann B, Senn H, Panel Members. Meeting Highlights: International expert consensus on the primary therapy of early breast cancer 2005. Ann Oncol 2005;16:1569-1583.

  6. 6. Cleator S, Ashworth A. Molecular profiling of breast cancer: clinical implications. Br J Cancer 2004;90:1120-1124.

  7. 7. Flores HO, Riveros RH, Sosa PA, Vázquez E. Mensaje bioquímico, vol. XXVII. Departamento de Bioquímica, Facultad de Medicina, Universidad Nacional Autónoma de México, Ciudad Universitaria, México, D. F; 2003. Disponible en http://smcg.cifn.unam.mx/MicroarreglosDNA-IFC/index.html

  8. 8. Quackenbush J. Microarray analysis and tumor classification. N Engl J Med 2006;354:2463–2472.

  9. 9. Perou CM, Sorlie T, Eisen MB, van de Rijn M, Jeffrey SS, Christian A. Rees CA, et al: Molecular portraits of human breast tumours. Nature 2000;406:747-752.

  10. 10. Perou CM, Jeffrey SS, van de Rijn M, Rees CA, Eisen MB, Ross DT, et al. Distinctive gene expression patterns in human mammary epithelial cells and breast cancers. Proc Natl Acad Sci USA 1999;96:9212–9217.

  11. 11. Brenton JD, Carey LD, Ahmed AA, Caldas C. Molecular classification and molecular forecasting of breast cancer: ready for clinical application? J Clin Oncol 2005;23:7350-7360.

  12. 12. van ‘t Veer LJ, Dai H, van de Vijver MJ, Yudong DH, Hart AA, Mao M, et al. Gene expression profiling predicts clinical outcome of breast cancer.Nature 2002;415:530-536.

  13. 13. Sorlie T, Tibshirani R, Parker J, Hastie T, Marron JS, Nobel A, et al. Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci USA 2003;100:8418-8423.

  14. 14. Simpson PT, Reis-Filho JS, Gale T, Lakhani SR. Molecular evolution of breast cancer. J Pathol 2005;205:248-254.

  15. 15. Mauriac L, Debled M, MacGrogan G. When will more useful predictive factors be ready for use? Breast 2005;14:617–623.

  16. 16. Sorlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H, et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA 2001;98:10869-10874.

  17. 17. Sotiriou C, Neo SY, McShane LM, Korn EL, Long PM, Jazaeri A, et al. Breast cancer classification and prognosis based on gene expression profiles from a population based study. Proc Natl Acad Sci USA 2003;100:10393-10398.

  18. 18. Weigelt B, Glas AM, Wessels LFA, Witteveen AT, Peterse JL, van’t Veer LJ. Gene expression profiles of primary breast tumors maintained in distant metastases. Proc Natl Acad Sci USA 2003;100:15901-15905.

  19. 19. Weigelt B, Hu Z, He X, Livasy C, Carey LA, Ewend MG, et al. Molecular portraits and 70-gene prognosis signature are preserved throughout the metastatic process of breast cancer. Cancer Res 2005;65:9155-9158.

  20. 20. Pusztai L, Mazouni CH, Anderson K, Wu Y, Symmans F. Molecular classification of breast cancer: limitations and potential. Oncologist 2006;11:868-877.

  21. 21. Gruvberger-Saal S, Cunliffe HE, Carr KM, Hedenfalk IA. Microarrays in breast cancer research and clinical practice¾the future lies ahead. Endocr Relat Cancer 2006;13:1017-1031.

  22. 22. Callagy G, Cattaneo E, Daigo Y, Happerfield L, Bobrow LG, Pharoah PD, et al. Molecular classification of breast carcinomas using tissue microarrays. Diagn Mol Pathol 2003;12:27-34.

  23. 23. Abd El-Rehim DM, Pinder SE, Paish CE, Bell J, Blamey RW, Robertson JF, et al. Expression of luminal and basal cytokeratins in human breast carcinoma. J Pathol. 2004;203:661-671.

  24. 24. Jacquemier J, Ginestier C, Rougemont J, Bardou VJ, Charafe-Jauffret E, Geneix J, et al. Protein expression profiling identifies subclasses of breast cancer and predicts prognosis. Cancer Res 2005;65:767-779.

  25. 25. Nielsen TO, Hsu FD, Jensen K, Cheang M, Karaca G, Hu Z, et al. Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma. Clin Cancer Res 2004;10:5367-5374.

  26. 26. Carey L, Perou C, Livasy C, Dressler L, Cowan D, Conway K, et al. Race, breast cancer subtypes, and survival in the Carolina breast cancer study. JAMA 2006;295:2492–2502.

  27. 27. Eden P, Ritz C, Rose C, Fernon M, Peterson C. ‘‘Good old’’ clinical markers have similar power in breast cancer prognosis as microarray gene expression profilers. Eur J Cancer 2004;40:1837-1841.

  28. 28. Carey LA, Perou CM, Dressler LG, Livasy CA, Geradts J, Cowan D, et al. Race and the poor prognosis basal-like breast cancer (BBC) phenotype in the population-based Carolina Breast Cancer Study. J Clin Oncol 2004(Suppl):abstr 9510.

  29. 29. Ring AE, Smith IE, Ashley S, Fulford LG, Lakhani SR. Oestrogen receptor status, pathological complete response and prognosis in patients receiving neoadjuvant chemotherapy for early breast cancer. Br J Cancer 2004;91: 2012-2017.

  30. 30. Rouzier R, Perou CM, Symmans WF Ibrahim N, Cristofanilli M, Anderson K, et al. Breast cancer molecular subtypes respond differently to preoperative chemotherapy. Clin Cancer Res 2005;11:5678-5685.

  31. 31. Paik S, Shak S, Tang G, Kim C, Baker J, Cronin M, et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med 2004;351: 2817-2826.

  32. 32. Miller KD, Burstein HJ, Elias A, Rugo HS, Cobleigh MA, Pegram MD, et al. Phase II study of SU11248, a multitargeted receptor tyrosine kinase inhibitor (TKI), in patients (pts) with previously treated metastatic breast cancer (MBC). J Clin Oncol 2005(Suppl):abstr 563.

  33. 33. Romond EH, Perez EA, Bryant J, Suman VJ, Geyer CE Jr, Davidson NE, et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 2005;353:1673-1684.

  34. 34. Piccart-Gebhart MJ, Procter M, Leyland-Jones B, Goldhirsch A, Untch M, Smith I, et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 2005;353:1659-1672.

  35. 35. Nagata Y, Lan K-H, Zhou X, Tan M, Esteva FJ, Sahin AA, et al. PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients. Cancer Cell 2004;6:117-127.

  36. 36. Tripathy D, Hassan S, Verma U, Gurnani P, Nandi A, Rosenblatt K. Phenotypic and proteomic alterations of acquired trastuzumab resistence. J Clin Oncol 2005;(Suppl):abstr 3121.

  37. 37. Foulkes WD, Brunet JS, Stefansson IM, Straume O, Chappuis PO, Bejin LR, et al. The prognostic implication of the basal-like (cyclin Ehigh/p27low/p53+/glomeruloid-microvascular-proliferation+) phenotype of BRCA1-related breast cancer. Cancer Res 2004;64:830-835.

  38. 38. Ribeiro-Silva A, Ramalho LN, Garcia SB, Brandao DF, Chahud S, Zucoloto S. p63 correlates with both BRCA1 and cytokeratin 5 in invasive breast carcinomas: further evidence for the pathogenesis of the basal phenotype of breast cancer. Histopathology 2005;47:458-466.

  39. 39. Goffin JR, Straume O, Chappuis PO, Brunet JS, Begin LR, Hamel N, et al. Glomeruloid microvascular proliferation is associated with p53 expression, germline BRCA1 mutations and an adverse outcome following breast cancer. Br J Cancer 2003;89:1031-1034.

  40. 40. Valladares A, Salamanca F, Madrigal-Bujaidar E, Arenas D. Identification of chromosomal changes with comparative genomic hybridization in sporadic breast cancer in Mexican women. Cancer Genet Cytogenet 2004;152:163-166.

  41. 41. García N, Salamanca F, Astudillo-De la Vegas H, Curiel-Quesada E, Alvarado I, Peñaloza R, et al. A molecular analysis by gene profiling reveals Bik/NBK overexpression in sporadic breast tumor samples of Mexican females. BMC Cancer 2005;5:93. Disponible en http://www.biomedcentral.com/1471-2407/93. Consultada el 6 de abril de 2007.

  42. 42. Valladares A, García N, Salamanca F, Curiel-Quezada E, Madrigal-Bujaidar E, Vergara MD, et al. Genetic expression profiles and chromosomal alterations in sporadic breast cancer in Mexican women. Cancer Genet Cytogenet 2006;170:147-151.




2020     |     www.medigraphic.com